Department of Orthopaedic Surgery, The Third Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510000, People's Republic of China.
The Third Medical Collage, Guangzhou University of Chinese Medicine, Guangzhou, 510000, People's Republic of China.
J Bone Miner Metab. 2024 Sep;42(5):516-528. doi: 10.1007/s00774-024-01516-4. Epub 2024 May 16.
Bone homeostasis depends on the regulation of β-catenin in osteoblasts. Glucocorticoids (GCs) are known to diminish β-catenin activity via Wnt pathway signaling, leading to osteoporosis. Conversely, activating β-catenin in osteoblasts through mitogen-activated protein kinase kinase kinase 2 (Mekk2) offers an innovative approach to combat GC-induced osteoporosis (GIOP). Fufang Zhenshu Tiaozhi (FTZ) capsules have shown effectiveness in treating GIOP, but the mechanisms behind this are still unclear.
In this study, Mekk2 knockout mice (Mekk2) was generated by CRISPR/Cas9. These mice were then subjected to Alcian Blue-Alizarin Red staining and immunofluorescence to assess their bone and cartilage development. To establish models of GIOP, both Mekk2 and wild-type (WT) mice were treated with dexamethasone (DXMS) and subsequently given FTZ capsules. We analyzed the resulting phenotypic changes in these mice using Micro-CT scans and histomorphological studies. Primary osteoblasts, isolated from both Mekk2 and WT mice, underwent qRT-PCR to measure key osteogenesis markers, including Runx2, Sp7, Bgalp, Col1a1 and Alp. Cells were then exposed to treatments with either FTZ or Wnt3a and the phosphorylation levels of β-catenin and Mekk2, along with the protein expression of Runx2, were evaluated using Western blotting and immunoprecipitation. Additionally, C3H10T1/2 cells transfected with TOPflash-luciferase and Renilla luciferase reporters were treated with FTZ and Wnt3a to measure β-catenin activity.
In our study, administering FTZ in vivo effectively prevented bone loss typically induced by GCs. However, it's important to note that this protective effect was substantially reduced in mice lacking Mekk2. Additionally, FTZ showed a significant ability to enhance osteogenic differentiation in primary osteoblasts, doing so by altering the expression of Mekk2. Intriguingly, the impact of FTZ on Mekk2 appears to function through a pathway separate from the traditional Wnt signaling route. Furthermore, our findings indicate that FTZ also promotes the deubiquitination of β-catenin, contributing further to its positive effects on bone health.
This study suggests that FTZ plays a significant role in protecting bone mass in cases of GIOP. The mechanism through which FTZ confers this benefit involves the activation of Mekk2/β-catenin signaling pathways, which represents a promising alternative strategy to counteract the deleterious effects of GIOP by augmenting osteoblastogenesis.
骨稳态依赖于成骨细胞中β-连环蛋白的调节。已知糖皮质激素(GCs)通过 Wnt 通路信号降低β-连环蛋白活性,导致骨质疏松症。相反,通过丝裂原活化蛋白激酶激酶激酶 2(Mekk2)激活成骨细胞中的β-连环蛋白为治疗 GC 诱导的骨质疏松症(GIOP)提供了一种创新方法。复方补肾调脂胶囊(FTZ)已被证明在治疗 GIOP 方面有效,但背后的机制仍不清楚。
本研究通过 CRISPR/Cas9 生成了 Mekk2 敲除小鼠(Mekk2)。然后,通过阿尔辛蓝-茜素红染色和免疫荧光评估这些小鼠的骨和软骨发育情况。为了建立 GIOP 模型,Mekk2 和野生型(WT)小鼠均用地塞米松(DXMS)处理,然后给予 FTZ 胶囊。我们使用 Micro-CT 扫描和组织形态学研究分析这些小鼠的表型变化。从 Mekk2 和 WT 小鼠中分离的原代成骨细胞进行 qRT-PCR 以测量关键成骨标志物,包括 Runx2、Sp7、Bgalp、Col1a1 和 Alp。然后用 FTZ 或 Wnt3a 处理细胞,并通过 Western blot 和免疫沉淀评估 β-连环蛋白和 Mekk2 的磷酸化水平以及 Runx2 的蛋白表达。此外,用 TOPflash-荧光素酶和 Renilla 荧光素酶报告基因转染的 C3H10T1/2 细胞用 FTZ 和 Wnt3a 处理,以测量 β-连环蛋白活性。
在我们的研究中,体内给予 FTZ 可有效预防糖皮质激素诱导的典型骨丢失。然而,重要的是要注意,在缺乏 Mekk2 的小鼠中,这种保护作用大大降低。此外,FTZ 显示出显著增强原代成骨细胞成骨分化的能力,其通过改变 Mekk2 的表达来实现。有趣的是,FTZ 对 Mekk2 的影响似乎通过与传统 Wnt 信号通路不同的途径发挥作用。此外,我们的研究结果表明,FTZ 还促进了 β-连环蛋白的去泛素化,进一步促进了其对骨骼健康的积极影响。
这项研究表明,FTZ 在保护 GIOP 时的骨量方面发挥了重要作用。FTZ 发挥这种益处的机制涉及 Mekk2/β-连环蛋白信号通路的激活,这代表了一种有前途的策略,通过增强成骨细胞生成来抵消 GIOP 的有害影响。